Our results demonstrate the efficacy of this improved treatment modality to specifically knockdown the disease-induced KDR overexpression, and robustly attenuate the severity of portosystemic collateral vessels in a murine model of portal hypertension. This evidence concerns the gene KDR and liver disorder.